

DAFTAR PUTAKA

- Abd Elsamea, M. H., Badr, A. N., Ibrahim, H. M., & Talaat, E. A. (2022). Renal arterial resistive index as a noninvasive biomarker of disease activity in lupus nephritis patients. *Egyptian Rheumatologist*, 44(3), 239–244. <https://doi.org/10.1016/j.ejr.2022.01.001>
- Arnaud, L., & van Vollenhoven, R. (2017). Advanced handbook of systemic lupus erythematosus. *Advanced Handbook of Systemic Lupus Erythematosus*, 1–167. <https://doi.org/10.1007/978-3-319-43035-5>
- Asif, S., Khan, A., Zahoor, S., Lashari, N., Haroon, M., & Khanum, A. (2022). Correlation Between Quantitative Anti-dsDNA Levels with Severity of Proteinuria in Systemic Lupus Erythematosus Patients. *Reumatologia Clinica*, 18(8), 464–468. <https://doi.org/10.1016/j.reuma.2021.06.002>
- Bagare, P. C., Borle, A., Baluni, P., Ekbote, G. G., & Sangale, S. (2024). Clinical Profile and Outcomes of Patients With Systemic Lupus Erythematosus. *Cureus*. <https://doi.org/10.7759/cureus.68541>
- Bai, Y., Tong, Y., Liu, Y., & Hu, H. (2018). Self-dsDNA in the pathogenesis of systemic lupus erythematosus. *Clinical and Experimental Immunology*, 191(1), 1–10. <https://doi.org/10.1111/cei.13041>
- Bassi, Nereo., Ghirardello, Alessandra., Iaccarino, Luciana., *et al.* (2020). Sex and gender differences in systemic lupus erythematosus. *Autoimmunity Reviews*, 19(2), 102489. <https://doi.org/10.1016/j.autrev.2020.102489>
- Bertsias, G. K., Ioannidis, J. P. A., Aringer, M. (2012). EULAR recommendations for the management of SLE with neuropsychiatric and renal involvement. **Annals of the Rheumatic Diseases**, 71(11), 1771–1781. <https://doi.org/10.1136/annrheumdis-2012-201940>
- Birmingham, D. J., Merchant, M., Waikar, S. S., Nagaraja, H., Klein, J. B., & Rovin, B. H. (2017). Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. *Nephrology Dialysis Transplantation*, 32(suppl_1), i71–i79. <https://doi.org/10.1093/ndt/gfw300>
- Chen Z, Yang M, Zhang Z, Hou Y, Liu J, Wang L. Complement C3 and C4 are valuable biomarkers for predicting activity and prognosis in lupus nephritis. *Front Immunol*. 2020;11:582012. <https://doi.org/10.3389/fimmu.2020.582012>
- Chessa E, Piga M, Floris A, Devilliers H, Cauli A, Mathieu A. Anti-dsDNA antibodies and renal flares in SLE: predictive role in disease monitoring. *Lupus Sci Med*. 2021;8(1):e000418. doi:10.1136/lupus-2021-000418.
- Cortes-Hernandez, J., Ordi-Ros, J., Labrador, M. (2005). Clinical predictors of renal relapse in patients with lupus nephritis: a follow-up of 62 patients. *Rheumatology (Oxford)*, 44(5), 624–630.
- Cozzani, E., Drosera, M., Gasparini, G., & Parodi, A. (2014). Serology of lupus erythematosus: Correlation between immunopathological features and clinical aspects. *Autoimmune Diseases*, 2014. <https://doi.org/10.1155/2014/321359>
- Dahlan S. (2014). *Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan*. Penerbit Salemba Medika.

- Dima, A., Jurcut, C., & Stoica, V. (2014). Predictive role of anti-dsDNA antibodies for lupus nephritis flares. *Lupus*, 23(7), 673–680. <https://doi.org/10.1177/0961203314524462>
- Direktorat Jendral Pencegahan dan Pengendalian Penyakit. (2018). *Pedoman Pengendalian Penyakit Lupus Eritematosus Sistemik (LES)*. Kementerian Kesehatan RI.
- Engli K.A, Handono K, Eko M.H , Susianti H , Gunawan A, K. H. . (2018). Proteinuria Severity in Lupus Nephritis is Associated with Anti-dsDNA Level and Immune Complex Deposit Location in Kidney. *Journal of Tropical Life Science*, 8(3), p.
- Fairhurst, Anna-Maria., Wandstrat, Arthur E., Wakeland, Edward K. (2021). Sex and gender differences in autoimmunity: Lupus as a model disease. *Nature Reviews Rheumatology*, 17(9), 513–524. <https://doi.org/10.1038/s41584-021-00633-0>
- Gulyas, K., Nagy, G., & Vánca, A. (2022). Anti-dsDNA levels are associated with renal and overall disease activity in SLE. *Clinical Immunology*, 241, 109001. <https://doi.org/10.1016/j.clim.2022.109001>
- Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. Prediction of renal flare in systemic lupus erythematosus patients by serial anti-dsDNA and complement levels. *Rheumatology (Oxford)*. 2007;46(2):274–9. doi:10.1093/rheumatology/kei310.
- Jakes, R. W., Bae, S. C., Louthrenoo, W., Mok, C. C., Navarra, S. V., & Kwon, N. (2012). Systematic review of the epidemiology of systemic lupus erythematosus in the asia-pacific region: Prevalence, incidence, clinical features, and mortality. *Arthritis Care and Research*, 64(2), 159–168. <https://doi.org/10.1002/acr.20683>
- Kasjmir, Y. I., Handono, K., Wijaya, L. K., Hamijoyo, L., Albar, Z., Kalim, H., Hermansyah. et al. (2011). Rekomendasi Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. In *Perhimpunan Reumatologi Indonesia*.
- Kovats, Susan. (2022). Estrogen receptors regulate innate immune cells and signaling pathways. *Cellular Immunology*, 371, 104463. <https://doi.org/10.1016/j.cellimm.2022.104463>
- Lee, W. S., & Amengual, O. (2020). B cells targeting therapy in the management of systemic lupus erythematosus. *Immunological Medicine*, 43(1), 16–35. <https://doi.org/10.1080/25785826.2019.1698929>
- Li, Y., Lee, P. Y., & Reeves, W. H. (2013). Complement activation in patients with systemic lupus erythematosus: a prospective study on renal outcomes. *Lupus*, 22(6), 602–609.
- M Saleh, A. (2013). *Penilaian Aktivitas Penyakit Lupus Eritematosus Sistemik Dengan Skor Sledai Di Departemen Ilmu Kesehatan Anak Rscm*. Fakultas Kedokteran Universitas Indonesia.
- Mailani, F. (2023). *Asuhan Keperawatan Pada Pasien SLE*. Adab.
- Manson JJ, Rahman A. Relationship between anti-dsDNA antibodies and disease activity in SLE measured by the SLEDAI-2K score. *Rheumatology (Oxford)*. 2016;55(5):940–3. doi:10.1093/rheumatology/kev297.
- Mina, R., Abulaban, K., Klein-gitelman, M., Eberhard, A., Ardoin, S., Singer, N.,

- Onel, K., Tucker, L. et al. (2017). *Naskah Penulis Naska Penuli Nas Pe Naskah Penulis Naska Penuli Nas Pe*. 513. <https://doi.org/10.1002/acr.22651>. Validasi Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH. Anti-dsDNA titers predict renal relapse in SLE patients with previous nephritis. *Am J Kidney Dis*. 2018;71(2):276–84. doi:10.1053/j.ajkd.2017.08.006.
- Mok, C. C., Ying, K. Y., Yim, C. W., Li, K. F., Ng, W. L., & Wong, R. W. (2000). Serum complement C3 and C4 levels in patients with systemic lupus erythematosus: correlation with disease activity and renal involvement. *Clinical Rheumatology*, 19(3), 191–195.
- Morand EF, Burlingame RW, Harris EN, Bernstein RM, Stollar BD. Anti-dsDNA antibodies as a predictor of renal flare in systemic lupus erythematosus. *Arthritis Rheum*. 2009;60(1):200–7. doi:10.1002/art.24622.
- Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Testoni C, et al. Low serum C3 and C4 levels as predictors of renal flare in lupus nephritis. *Autoimmun Rev*. 2009;8(1):36–40. <https://doi.org/10.1016/j.autrev.2008.07.023>
- Nabila F. , Miro S. , Effendi R. , Almurdi A. , Yulia D. , & Putra S.. Hubungan tingkat aktivitas penyakit lupus eritematosus sistemik dengan derajat gangguan fungsi ginjal pada pasien lupus eritematosus sistemik. *Jurnal Ilmu Kesehatan Indonesia* 2024;5(2):138-144. <https://doi.org/10.25077/jikesi.v5i2.1103>
- Narvaez, J., Ricse, M., & Gomà, M. (2012). Clinical utility of anti-dsDNA antibody levels in SLE patients with renal involvement. *Lupus*, 21(12), 1285–1291. <https://doi.org/10.1177/0961203312458469>
- Navarra, S. V., Leynes, M. S., Naqvi, F. (2011). Association between complement levels and lupus nephritis activity in Asian patients with SLE. *Lupus*, 20 (12), 1396–1403.
- Pisetsky, D. S., & Lipsky, P. E. (2011). Anti-dsDNA antibodies—quintessential biomarkers of SLE. *Nature Reviews Rheumatology*, 7, 102–110. <https://doi.org/10.1038/nrrheum.2010.200>
- Pons-Estel, G. J., Ugarte-Gil, M. F., & Alarcón, G. S. (2017). Epidemiology of systemic lupus erythematosus. *Expert Review of Clinical Immunology*, 13(8), 799–814. <https://doi.org/10.1080/1744666X.2017.1327352>
- Rees, F., Doherty, M., Grainge, M. J., Lanyon, P., & Zhang, W. (2017). The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. *Rheumatology (United Kingdom)*, 56(11), 1945–1961. <https://doi.org/10.1093/rheumatology/kex260>
- Rekvig OP. The dsDNA–anti-dsDNA antibody paradigm in SLE: Are we moving towards resolution? *Front Immunol*. 2019;10:1103. doi:10.3389/fimmu.2019.01103.
- Rovin, B. H., Parikh, S. V., & Hebert, L. A. (2015). Biomarkers for lupus nephritis: the quest continues. *Journal of the American Society of Nephrology*, 26(12), 2935–2943. <https://doi.org/10.1681/ASN.2015040419>
- Ruiz-Irastorza, G., Ugarte, A., Egurbide, M. V. (2010). Changes in anti-dsDNA and complement levels in SLE patients treated with mycophenolate. *Annals of the*

- Rheumatic Diseases, 69(11), 2055–2056.
<https://doi.org/10.1136/ard.2009.125203>
- Sato T, Miyake K, Tsumura H, Shinozaki M, Yoshida S, Takano M, et al. Clinical significance of decreased serum complement C3 levels in patients with lupus nephritis. *Rheumatol Int.* 2017;37(5):829–35. <https://doi.org/10.1007/s00296-017-3683-9>
- Sun, Chao., Molineros, Jorge E., Looger, Loren L., Zhou, Xiaoting., Okada, Yukinori., Maiti, Ashis K., et al. (2022). Genetic risk and estrogen-dependent mechanisms in systemic lupus erythematosus. *Nature Communications*, 13, 2336. <https://doi.org/10.1038/s41467-022-29991-1>
- Shizuma, T. (2015). Liver Complications Associated with Systemic Lupus Erythematosus. *Rheumatology: Current Research*, 05(01), 1–5. <https://doi.org/10.4172/2161-1149.1000146>
- Somers, EC Marder, W Cagnoli, P Lewis, E., & Deguire, P Gordon, C. (2014). Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus. *Arthritis Rheumatol.*, 66(2), 369–378. <https://doi.org/10.1002/art.38238>. Population-Based
- Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Serial autoantibodies in predicting renal flares in systemic lupus erythematosus. *Arthritis Care Res.* 2010;62(12):1776–83. doi:10.1002/acr.20221
- Suarjana, I. N. (2018). Lupus Eritematosus Sistemik. *Buku Ajar Ilmu Penyakit Dalam, 1702612069*, 1–13.
- Sumariyono, Kalim Handono, D. (2019). *Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*. Perhimpunan Reumatologi Indonesia. <https://doi.org/10.2307/3460461>
- Sumariyono., Kalim, H., Setyohadi, B., Hidayat R., Najirman., Hamijoyo L., et al. (2019). *Rekomendasi Perhimpunan Reumatologi Indonesia untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik*. (Ed. Revisi). Perhimpunan Reumatologi Indonesia.
- Susianti, Hani. Handono, K. (2012). *Perkembangan Petanda Biologik*. Ub Press.
- Tanzilia, M. F., Tambunan, B. A., & Dewi, D. N. S. S. (2021). Tinjauan Pustaka: Patogenesis Dan Diagnosis Sistemik Lupus Eritematosus. *Syifa' MEDIKA: Jurnal Kedokteran Dan Kesehatan*, 11(2), 139. <https://doi.org/10.32502/sm.v11i2.2788>
- Wu LH, Yu F, Tan Y, Qu Z, Chen MH, Wang SX, et al. Correlation between complement levels and disease activity in lupus nephritis patients. *Lupus*. 2016;25(13):1387–95. <https://doi.org/10.1177/0961203316651741>
- Yu, F., Haas, M., Glassock, R., & Zhao, M. H. (2010). Predictive value of complement C3 and C4 for renal histopathology and outcome in lupus nephritis. *Clinical Journal of the American Society of Nephrology*, 5(9), 1533–1539.
- Yuliasih. (2020). Perkembangan Patogenesis dan Tata Laksana Systemic Lupus Erythematosus. *Jurnal Universitas Airlangga*, 4(2020), 38–54.
- Zhang Y, Li M, Zhang J, Wang X, Ma J, Peng L, et al. Correlation of anti-dsDNA antibodies with renal involvement and disease activity in systemic lupus erythematosus. *Clin Rheumatol.* 2020;39(12):3625–34. doi:10.1007/s10067-

020-05137-5.

Zickert A, Svenungsson E, Gunnarsson I. Low C3 and C4 levels in systemic lupus erythematosus are associated with active renal disease and predict renal outcome. *Lupus Sci Med.* 2014;1(1):e000026. <https://doi.org/10.1136/lupus-2014-000026>